SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-047243
Filing Date
2024-04-24
Accepted
2024-04-24 07:07:51
Documents
19
Period of Report
2024-06-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A amlx-20240424.htm   iXBRL DEF 14A 1597196
2 GRAPHIC img111436731_0.jpg GRAPHIC 103455
3 GRAPHIC img111436731_1.jpg GRAPHIC 103455
4 GRAPHIC img111436731_2.jpg GRAPHIC 137788
5 GRAPHIC img111436731_3.jpg GRAPHIC 131579
6 GRAPHIC img111436731_4.jpg GRAPHIC 138533
7 GRAPHIC img111436731_5.jpg GRAPHIC 111951
8 GRAPHIC img111436731_6.jpg GRAPHIC 262959
9 GRAPHIC img111436731_7.jpg GRAPHIC 263352
  Complete submission text file 0000950170-24-047243.txt   5377099

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20240424.xsd EX-101.SCH 42673
22 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20240424_htm.xml XML 320026
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41199 | Film No.: 24866706
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)